HC Wainwright Lifts Earnings Estimates for Arcus Biosciences

Arcus Biosciences, Inc. (NYSE:RCUS) – HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Arcus Biosciences in a note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($1.01) per share for the quarter, up from their prior estimate of ($1.18). HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.66) EPS, FY2027 earnings at ($3.62) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at ($0.71) EPS.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Wednesday, February 25th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The firm had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. During the same quarter last year, the company earned ($1.03) earnings per share. The company’s revenue was down 8.3% on a year-over-year basis.

Several other equities research analysts also recently issued reports on the company. Morgan Stanley restated an “equal weight” rating and set a $20.00 target price (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. Truist Financial set a $30.00 price objective on Arcus Biosciences in a research note on Friday, December 12th. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.30.

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $23.86 on Monday. The firm’s 50 day moving average is $21.58 and its 200 day moving average is $18.66. The stock has a market capitalization of $2.99 billion, a P/E ratio of -7.23 and a beta of 0.85. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $26.40. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.16.

Hedge Funds Weigh In On Arcus Biosciences

Several large investors have recently modified their holdings of the stock. AQR Capital Management LLC raised its holdings in Arcus Biosciences by 253.9% during the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock valued at $714,000 after buying an additional 65,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Arcus Biosciences by 10.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock valued at $297,000 after acquiring an additional 3,565 shares during the last quarter. Millennium Management LLC raised its stake in shares of Arcus Biosciences by 29.2% in the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock valued at $9,378,000 after acquiring an additional 270,253 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock valued at $7,177,000 after acquiring an additional 470,755 shares during the period. Finally, Strs Ohio bought a new stake in shares of Arcus Biosciences in the 1st quarter worth about $67,000. Institutional investors own 92.89% of the company’s stock.

Insider Transactions at Arcus Biosciences

In related news, COO Jennifer Jarrett sold 11,225 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $245,603.00. Following the completion of the transaction, the chief operating officer directly owned 203,007 shares of the company’s stock, valued at approximately $4,441,793.16. This represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Juan C. Jaen sold 82,997 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $24.71, for a total value of $2,050,855.87. Following the completion of the sale, the president directly owned 954,063 shares in the company, valued at approximately $23,574,896.73. The trade was a 8.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 263,987 shares of company stock valued at $6,025,620 in the last ninety days. Corporate insiders own 9.60% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.